Business Wire

Newly published trial results showed spesolimab significantly improved signs and symptoms of flare in rare, life-threatening skin disease, generalized pustular psoriasis

Share

Boehringer Ingelheim announced today the publication in the New England Journal of Medicine of new data from the pivotal Phase II EffisayilTM 1 trial, which showed spesolimab, a first-in-class investigational treatment, significantly improved signs and symptoms of generalized pustular psoriasis (GPP) in patients experiencing a flare.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211222005031/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

GPP is a rare, life-threatening neutrophilic skin disease, which is distinct from plaque psoriasis. It is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus).2,3,4 There is a high unmet need for treatments that can rapidly and completely resolve the symptoms of GPP flares. Flares greatly affect a person’s quality of life5 and can lead to hospitalization with life-threatening complications, such as heart failure, renal failure and sepsis and even death.6

In the 12-week trial, 53 patients experiencing a GPP flare were treated with a single intravenous dose of spesolimab or placebo. Most patients at the outset of the trial had a high or very high density of pustules and impaired quality of life. Results after one week demonstrated that:

  • 54% of patients treated with spesolimab showed no visible pustules compared to 6% of those treated with placebo;
  • 43% of patients treated with spesolimab showed clear/almost clear skin compared to 11% of those in the placebo group.1

Pustular and skin clearance continued for the duration of the study. This clearance was accompanied by clinically significant improvements in quality of life and symptoms such as pain and fatigue, compared to placebo.1

Over the 12-week duration of the study, non-serious infections rates were higher in the spesolimab group compared with placebo, with no pattern regarding pathogen and affected organs. Two patients reported to have drug reactions with eosinophilia and systemic symptoms.

“With no approved treatments in the U.S. or E.U. for GPP flares, there is a significant unmet need for people with this distressing and painful skin condition, that often requires emergency care,” said Mark Lebwohl, MD, lead investigator and publication author, and Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai, Kimberly and Eric J. Waldman Department of Dermatology, New York. “These clinical trial results show that spesolimab has the potential to completely clear the skin of the signs and symptoms of a GPP flare after only one week, with sustained effect observed for up to 12 weeks.”

The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for the treatment of GPP, and Breakthrough Therapy Designation for spesolimab for the treatment of GPP flares. This designation is for therapies treating serious or life-threatening conditions where early clinical evidence suggests a substantial improvement compared to existing treatments. The Chinese Regulatory Authority Centre for Drug Evaluation (CDE) also recently granted Breakthrough Therapy Designation for spesolimab for the treatment of GPP flares.

“At Boehringer Ingelheim, we are committed to finding transformative therapies to help advance treatment for people who urgently need them,” said Dr Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, Boehringer Ingelheim. “The findings indicate that spesolimab may have a significant and positive impact on patients experiencing a GPP flare.”

The clinical program for spesolimab includes two other trials that are currently underway. First, the Effisayil-2 trial is designed to investigate spesolimab as a maintenance treatment to prevent the occurrence of GPP flares. The Effisayil-ON trial is an open label five-year extension study to investigate the longer term efficacy and safety of spesolimab in patents with GPP.7,8

Please click on the following link for ‘Notes to Editors’: https://www.boehringer-ingelheim.com/human-health/skin-diseases/gpp/spesolimab-phase-ii-data

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR

Dr Julia Fass
Phone: +49 (6132) 77 95614
Fax: +49 (6132) 77 6601
Email: press@boehringer-ingelheim.com

Additional information
www.boehringer-ingelheim.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rosenberger Announced the Spinoff of Antenna and Coverage Solution Product Portfolio with a New Brand Entity, PROSE24.1.2022 12:52:00 EET | Press release

The Rosenberger Group today announced the spinoff of its antenna and coverage solution product portfolio with a new brand entity, PROSE. The strategic focus of PROSE will be towards the development of base station antennas, microwave antennas, indoor and outdoor coverage solutions, Open RAN sub-systems and related services. PROSE will be headed by Mrs. Aili Liu, the co-founder and former president of Rosenberger Asia Pacific and Rosenberger Technologies. As an independent entity, PROSE, with its lean, agile, and decentralized organizational structure, will be better placed to serve global customers and manage growth by bringing new technologies and solutions at a rapid rate, aligned with the increasing needs of customers. Its product portfolio will uphold Rosenberger’s tradition of the highest innovation and quality while delivering improved technology expertise and enhanced customer support. The company consists of 3500+ people, with 25 subsidiaries sales/service offices, 3 factories

H.I.G. Infrastructure to Acquire EYSA24.1.2022 12:30:00 EET | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with more than $47 billion of equity capital under management, announced that an affiliate has signed a definitive agreement to acquire EYSA Group (“EYSA” or the “Company”), a market leading provider of smart mobility solutions. The transaction is subject to regulatory approvals. The transaction is led by the H.I.G. Infrastructure Partners fund. Terms were not disclosed. EYSA is headquartered in Madrid, Spain, with an international presence in the USA, Mexico, Colombia, Ecuador and Brazil. Leveraging on “ParkXplorer”, its proprietary IT platform, the Company has become a one-stop-shop for more than 100 cities across Spain, Latin America and the USA. EYSA has long term relationships with municipalities and private clients who desire comprehensive, automated solution integrating all their mobility needs. Over the past several years, EYSA has evolved from a purely regulated parking operator, to an integrated tech-enab

European Manufacturers Embrace the Cloud to Improve Their Agility24.1.2022 12:00:00 EET | Press release

European manufacturing firms are embracing cloud-based technologies and services to accelerate their go-to-market plans and improve digital marketing efforts, according to a new report published today by Information Services Group (ISG) (Nasdaq: III), a leading global technology research and advisory firm. The 2021 ISG Provider Lens™ Manufacturing Industry Services Report for Europe finds manufacturers on the continent also looking to the cloud to enable direct-to-consumer business models. “Manufacturers in Europe are turning to the cloud to increase their business agility,” said Christian Decker, EMEA partner, ISG Smart Manufacturing. “And they are turning to manufacturing services providers to help them create new reference architectures and bring resiliency to their operations.” In addition, manufacturing firms want service providers to help them establish robust configuration management databases and leverage automated testing, including shift-left techniques, the report says. The

Zyxel Communications to Join Open Networking Foundation Aligning With Projects Focused on Broadband Transformation24.1.2022 10:00:00 EET | Press release

Zyxel Communications now is a member of the Open Networking Foundation (ONF), a non-profit operator-led consortium driving transformation of access and edge network infrastructure. Zyxel will join two of the foundation’s ongoing projects: VOLTHA and SEBA. VOLTHA is an open-source project creating a hardware abstraction for broadband access equipment. It supports the principle of multi-vendor, disaggregated, “any broadband access a service” for the central office. VOLTHA is an access network component of SEBA – a lightweight platform based on a variant of R-CORD. SEBA supports a multitude of virtualized access technologies at the edge of the carrier network, including PON and G.Fast. Through its ONF membership, Zyxel will help bring state of the art white-box hardware to other community members and share expertise in manufacturing and production, driving community cooperation, and delivering easy-to-deploy hardware and software solutions to the world’s service providers. “By bringing Zy

Health Canada Approves Ipsen’s Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva24.1.2022 09:00:00 EET | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the Health Canada approval of Sohonos (palovarotene capsules), an oral selective retinoic-acid receptor gamma (RARγ) agonist indicated to reduce the formation of heterotopic ossification (HO; new bone formation) in adults and children aged 8 years and above for females and 10 years and above for males with fibrodysplasia ossificans progressiva (FOP).1 Sohonos is approved for the treatment of patients with FOP for both chronic use, and for flare-ups, in these patient populations. This decision marks the first approval for Sohonos worldwide. Dr. Howard Mayer, Executive Vice President and Head of Research and Development, Ipsen, said “FOP is a progressive and debilitating condition which has such a profound impact on patients, and their families. Until today, there was no approved medicine, and we are proud to bring this important new medicine to the FOP community.” FOP is characterized by new bone formation outside of the

Altasciences Chosen by Virpax Pharmaceuticals, Inc. to Conduct First-in-Human Study of Epoladerm™ for Chronic Pain Associated with Osteoarthritis of the Knee21.1.2022 19:00:00 EET | Press release

Altasciences is pleased to have been chosen by Virpax® Pharmaceuticals, Inc. (“Virpax”) (NASDAQ:VRPX) to conduct a first-in-human study of Epoladerm™ (diclofenac epolamine) for chronic pain associated with osteoarthritis of the knee. This treatment is supplied in a pre-filled device for administration as a topical spray film. The study will be conducted in Q2 2022 at Altasciences’ clinical pharmacology unit in Montreal, Canada. “We look forward to working with Altasciences to accelerate the development of this analgesic treatment and provide robust data in support of the 505(b)(2) FDA approval pathway,” stated Virpax’s Chairman & CEO, Anthony P. Mack. Virpax’s proprietary technology provides a pre-filled canister for the therapeutic application of a clear, fast-drying spray film that is thinner than a standard liquid bandage. This technology offers convenience and eliminates the need for messy creams or gels. Altasciences leverages decades of experience conducting first-in-human clinic

OMRON Healthcare Remote Patient Monitoring Services Win “Best of” Honors at CES 202221.1.2022 18:21:00 EET | Press release

OMRON Healthcare, Inc., the global leader in remote blood pressure monitoring and personal health technology, spotlighted its new remote patient monitoring services at the 2022 Consumer Electronics Show (CES) and won “Best of” honors for its offerings in the U.K. and U.S: Hypertension Plus by OMRON in the U.K. was selected as a TWICE Picks Awards winner for the 2022 TWICE, Residential Systems and TechRadar Pro Picks Awards VitalSight™ by OMRON in the U.S. was recognised as an INSIDER “Best of” CES selection These remote patient monitoring services gained recognition at the world’s largest innovation show as breakthrough health technology designed to foster greater active health condition management, strengthen the patient-physician connection, and guide behavior change to reduce health risks, while advancing the company’s mission of Going for Zero heart attacks and strokes. “OMRON developed Hypertension Plus as the first step toward transforming chronic care in the U.K., while VitalSig

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom